Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P4GU | ISIN: US14147L1089 | Ticker-Symbol: XE7C
Tradegate
24.04.25
15:34 Uhr
2,560 Euro
-0,025
-0,97 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CARDIFF ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
CARDIFF ONCOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,4852,52019:57
2,4852,52019:54

Aktuelle News zur CARDIFF ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.04.Cardiff Oncology, Inc.: Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer72- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April 15...
► Artikel lesen
15.04.Cardiff Oncology, Inc.: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)152SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
► Artikel lesen
14.04.Piper Sandler raises Cardiff Oncology stock target to $109
03.04.Lucid Capital Markets sets $14 target on Cardiff Oncology stock8
CARDIFF ONCOLOGY Aktie jetzt für 0€ handeln
12.03.Cardiff Oncology Surges 18%54
28.02.Cardiff Oncology stock target raised to $17 at H.C. Wainwright14
27.02.Cardiff Oncology, Inc. Full Year Loss Rises12
27.02.Cardiff Oncology plans mixed shelf offering10
27.02.Cardiff Oncology GAAP EPS of -$0.95 beats by $0.03, revenue of $0.68M beats by $0.07M19
27.02.Cardiff Oncology, Inc.: Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update98- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer ("mCRC") clinical trial (CRDF-004) - - Priced oversubscribed $40 million...
► Artikel lesen
27.02.Cardiff Oncology, Inc. - 10-K, Annual Report3
20.02.Cardiff Oncology, Inc.: Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update11
06.01.Cardiff Oncology, Inc. - 8-K, Current Report20
11.12.24CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study23
11.12.24Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More3
10.12.24What's Going On With Cardiff Oncology Stock On Tuesday?16
10.12.24Cardiff Oncology Prices About $40 Mln Oversubscribed Offering To Fund Colorectal Cancer Trials22
10.12.24Cardiff Oncology sets $2.60 price for stock offering10
10.12.24Cardiff Oncology legt Preis für Aktienemission bei 2,60 US-Dollar fest19
10.12.24Cardiff Oncology, Inc.: Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering10
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4